COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Hyperglycemia in a Coronary Intensive Care Unit

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00984737
Recruitment Status : Completed
First Posted : September 25, 2009
Last Update Posted : September 25, 2009
Information provided by:
Baskent University

Brief Summary:
Newly diagnosed hyperglycemia (NDH) and stress hyperglycemia (SH) during acute illness is reported as a non-physiological condition in hospitals. The investigators aim is to determine the rate of NDH and SH among cases admitted to coronary ICU with acute coronary disease and to inquire the relationship of SH with disease severity and functional outcomes such as longevity of ICU stay.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Hyperglycemia Blood Glucose Myocardial Ischemia Drug: Insulin Not Applicable

Detailed Description:

Patients with acute coronary heart disease admitted to the emergency room will be recruited consecutively. Admission plasma glucose (APG) and fasting plasma glucose (FPG); the first morning after admission, measurements will be obtained and each participant will be subjected to capillary glucose measurement (CGM) every six hours within the first day.

Patients will be separated into 4 groups:

GROUP 1: Normoglycemic cases GROUP 2: Newly diagnosed hyperglycemic cases Group 2a: Unrecognized diabetes, hbA1c: >6.0% Group 2b: Stress hyperglycemia <6.0%. GROUP 3: Known diabetes Age, gender, co-morbidities on admission, adverse outcomes in hospital, duration of stay in coronary ICU, deaths, drugs, and glucose levels will be all recorded.

Throughout the hospital stay of Group 2 and Group 3, CGMs were performed and treated when necessary (target glucose<180mg/dl).

Acute Physiology and Chronic Health Evaluation II (APACHE-II); a severity of disease classification system was used for each case.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Diagnostic
Official Title: Newly Diagnosed Hyperglycemia and Stress Hyperglycemia in a Coronary Intensive Care Unit
Study Start Date : May 2007
Actual Primary Completion Date : November 2008
Actual Study Completion Date : November 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hyperglycemia

Intervention Details:
  • Drug: Insulin

    Capillary glucose measurements of Group 2 and Group 3 will be performed during hospitalization and will be treated when they are over 180mg/dl.

    Short acting oral anti-diabetic drugs will be given to patients who refuse insulin injection.

Primary Outcome Measures :
  1. To determine the prevalence of newly diagnosed hyperglycemia in coronary ICU.

Secondary Outcome Measures :
  1. To search for the cases with stress hyperglycemia and inquire its relationship with disease severity and functional outcomes, such as longevity of ICU stay.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with acute coronary syndrome (non ST segment elevation)and myocardial infarction admitted to coronary ICU only via emergency room

Exclusion Criteria:

  • Patients admitted to coronary ICU from other hospital wards
  • Patients with any disease that will need drugs that may interfere with blood glucose negatively (mannitol, glucocorticoids, vasopressor agents, etc.)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00984737

Layout table for location information
Baskent University Faculty of Medicine, Adana Medical Center
Adana, Turkey, 01250
Sponsors and Collaborators
Baskent University
Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00984737    
Other Study ID Numbers: KA07/101
First Posted: September 25, 2009    Key Record Dates
Last Update Posted: September 25, 2009
Last Verified: September 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Ischemia
Pathologic Processes
Glucose Metabolism Disorders
Metabolic Diseases
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Hypoglycemic Agents
Physiological Effects of Drugs